Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma : vimarsana.com

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

BALTIMORE, Jan. 22, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics company and developer of best-in-class personalized MRD technology , has entered a research collaboration with...

Related Keywords

Helsinki , Eteläuomen Läi , Finland , Hamburg , Germany , United States , Maryland , Baltimore , Americans , Dan Edelstein , Steven Katz , Research Use , Trisalus Life Sciences , Quest Diagnostics , Johns Hopkins School Of Medicine , Pressure Enabled Drug Delivery , Vice President , General Manager , Chief Medical Officer , Trisalus Life , Johns Hopkins School , Research Use Only , Markets ,